🔴 SeaStar Medical is trading 10.5% down in pre-market

SeaStar Medical is trading at $1.79, down 10.50% in pre-market, with no specific negative company catalyst identified in available reporting.

• On November 3, the FDA confirmed QUELIMMUNE’s post-approval study requirements were fulfilled, a positive access-related development; reports do not establish it as the cause of the decline.
• Major U.S. futures were higher, while trading volume and pre-market activity levels were unavailable.